JP2017508468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508468A5 JP2017508468A5 JP2016556702A JP2016556702A JP2017508468A5 JP 2017508468 A5 JP2017508468 A5 JP 2017508468A5 JP 2016556702 A JP2016556702 A JP 2016556702A JP 2016556702 A JP2016556702 A JP 2016556702A JP 2017508468 A5 JP2017508468 A5 JP 2017508468A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cell
- engineered
- specific
- uniprot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 34
- 102100031780 Endonuclease Human genes 0.000 claims description 28
- 108010042407 Endonucleases Proteins 0.000 claims description 28
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 24
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 15
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 12
- -1 CD78 Proteins 0.000 claims description 12
- 102000001301 EGF receptor Human genes 0.000 claims description 12
- 108060006698 EGF receptor Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 230000001506 immunosuppresive effect Effects 0.000 claims description 12
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 claims description 11
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 11
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 11
- 230000007018 DNA scission Effects 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 8
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 8
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 8
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 8
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 8
- 102100034872 Kallikrein-4 Human genes 0.000 claims description 8
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 8
- 102100035721 Syndecan-1 Human genes 0.000 claims description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 108010024383 kallikrein 4 Proteins 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 claims description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 101710145634 Antigen 1 Proteins 0.000 claims description 4
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 4
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 101150031358 COLEC10 gene Proteins 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102000013392 Carboxylesterase Human genes 0.000 claims description 4
- 108010051152 Carboxylesterase Proteins 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 108010036395 Endoglin Proteins 0.000 claims description 4
- 102100037241 Endoglin Human genes 0.000 claims description 4
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 4
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 4
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 4
- 102100037362 Fibronectin Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 101000994322 Homo sapiens Integrin alpha-8 Proteins 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 101000891028 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 claims description 4
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims description 4
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 102100032825 Integrin alpha-8 Human genes 0.000 claims description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 4
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 4
- 108010028275 Leukocyte Elastase Proteins 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100033174 Neutrophil elastase Human genes 0.000 claims description 4
- 102100040348 Peptidyl-prolyl cis-trans isomerase FKBP11 Human genes 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 102100040120 Prominin-1 Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 4
- 101150037769 TRX2 gene Proteins 0.000 claims description 4
- 108010017842 Telomerase Proteins 0.000 claims description 4
- 102000007000 Tenascin Human genes 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 108010034949 Thyroglobulin Proteins 0.000 claims description 4
- 102000009843 Thyroglobulin Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 108010057085 cytokine receptors Proteins 0.000 claims description 4
- 102000003675 cytokine receptors Human genes 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 229960002175 thyroglobulin Drugs 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 3
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 3
- 101800000385 Transmembrane protein Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 108010079891 prostein Proteins 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 102100037265 Podoplanin Human genes 0.000 claims 1
- 108010055246 excisionase Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470119 | 2014-03-11 | ||
| DKPA201470119 | 2014-03-11 | ||
| PCT/EP2015/055097 WO2015136001A1 (en) | 2014-03-11 | 2015-03-11 | Method for generating t-cells compatible for allogenic transplantation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020051964A Division JP7105266B2 (ja) | 2014-03-11 | 2020-03-24 | 同種移植に適合するｔ細胞を作製するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508468A JP2017508468A (ja) | 2017-03-30 |
| JP2017508468A5 true JP2017508468A5 (cg-RX-API-DMAC7.html) | 2018-04-19 |
| JP6681837B2 JP6681837B2 (ja) | 2020-04-15 |
Family
ID=50336023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556702A Active JP6681837B2 (ja) | 2014-03-11 | 2015-03-11 | 同種移植に適合するｔ細胞を作製するための方法 |
| JP2020051964A Active JP7105266B2 (ja) | 2014-03-11 | 2020-03-24 | 同種移植に適合するｔ細胞を作製するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020051964A Active JP7105266B2 (ja) | 2014-03-11 | 2020-03-24 | 同種移植に適合するｔ細胞を作製するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20170016025A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3116902B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6681837B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102228828B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106103475B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015228844B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016019071A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2942113C (cg-RX-API-DMAC7.html) |
| DK (3) | DK4368705T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2782125T3 (cg-RX-API-DMAC7.html) |
| HU (3) | HUE048558T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL247064B (cg-RX-API-DMAC7.html) |
| MX (1) | MX373460B (cg-RX-API-DMAC7.html) |
| PL (3) | PL3693384T3 (cg-RX-API-DMAC7.html) |
| PT (3) | PT3116902T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2752933C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015136001A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (208)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8409861B2 (en) * | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| KR102595473B1 (ko) * | 2014-04-18 | 2023-10-30 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
| US20170224731A1 (en) * | 2014-06-10 | 2017-08-10 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3215168B1 (en) * | 2014-10-31 | 2023-08-02 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| EP3245286A4 (en) * | 2015-01-17 | 2018-07-11 | Zhejiang University | Modified cells evoking reduced immunogenic responses |
| CA2973529A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| WO2017001572A1 (en) * | 2015-06-30 | 2017-01-05 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| AU2016307050A1 (en) | 2015-08-11 | 2018-02-15 | Cellectis | Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation |
| US11091780B2 (en) | 2015-09-18 | 2021-08-17 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
| EP3940070A1 (en) | 2015-10-05 | 2022-01-19 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| KR20250013291A (ko) | 2015-10-05 | 2025-01-31 | 프리시젼 바이오사이언시스 인코포레이티드 | 변형된 인간 t 세포 수용체 알파 불변 영역 유전자를 포함하는 유전자 변형된 세포 |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| SG11201803173VA (en) | 2015-10-23 | 2018-05-30 | Harvard College | Nucleobase editors and uses thereof |
| CN108699557B (zh) * | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| EP3389677B1 (en) * | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
| ES2901000T3 (es) * | 2015-12-23 | 2022-03-21 | Prec Biosciences Inc | Meganucleasas de ingeniería con secuencias de reconocimiento encontradas en el gen de la microglobulina beta-2 humana |
| IL291971B2 (en) * | 2016-03-04 | 2025-04-01 | Editas Medicine Inc | CRISPR–CPF1 related methods, compositions and components for cancer immunotherapy |
| WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
| WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
| JP7145761B2 (ja) * | 2016-04-22 | 2022-10-03 | クレイジュ・メディカル・カンパニー・リミテッド | 細胞免疫療法の組成物および方法 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11078483B1 (en) | 2016-09-02 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for measuring and improving CRISPR reagent function |
| AU2017338827B2 (en) | 2016-10-03 | 2023-08-31 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| AU2017347637B2 (en) * | 2016-10-19 | 2024-02-15 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| JP7236380B2 (ja) * | 2016-10-19 | 2023-03-09 | セレクティス | 治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| CN110268050B (zh) * | 2017-01-10 | 2024-09-13 | 综合医院公司 | 经修饰的t细胞和它们的使用方法 |
| CN107058230B (zh) * | 2017-01-20 | 2020-03-24 | 山东兴瑞生物科技有限公司 | 一种沉默t细胞抗原受体的t淋巴细胞的制备方法 |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| WO2018178377A1 (en) | 2017-03-31 | 2018-10-04 | Cellectis Sa | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| JP7170666B2 (ja) * | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3631468A1 (en) * | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| US11851677B2 (en) * | 2017-06-13 | 2023-12-26 | Fate Therapeutics, Inc. | Composition and methods for inducing myeloid suppressive cells and use thereof |
| EP3638783A4 (en) * | 2017-06-16 | 2021-03-10 | Sangamo Therapeutics, Inc. | TARGETED T-LYMPHOCYTE AND / OR HLA RECEPTOR INTERRUPTION |
| US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| WO2019006330A1 (en) * | 2017-06-30 | 2019-01-03 | Indiana University Research And Technology Corporation | COMPOSITIONS AND METHODS FOR DETECTING REACTIVITY TO ALS |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| EP3640333A4 (en) | 2017-07-14 | 2020-12-30 | Cure Genetics Co., Ltd | GENE EDITING SYSTEM AND GENE EDITING METHOD |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| US20200261502A1 (en) * | 2017-09-08 | 2020-08-20 | Carsgen Therapeutics Co., Ltd. | Genetically engineered t cell and application thereof |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CN111183158A (zh) * | 2017-10-05 | 2020-05-19 | 河谷细胞有限公司 | Nk细胞上的基于脂质的抗原和t细胞受体 |
| AU2018352592C1 (en) | 2017-10-16 | 2025-09-25 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| WO2019076486A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
| CN109694854B (zh) * | 2017-10-20 | 2023-11-21 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| CN109750035B (zh) * | 2017-11-02 | 2020-06-05 | 上海邦耀生物科技有限公司 | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA |
| WO2019097083A1 (en) * | 2017-11-20 | 2019-05-23 | Tessa Therapeutics Pte. Ltd. | Modified k562 cell |
| WO2019110693A1 (en) * | 2017-12-05 | 2019-06-13 | Celyad S.A. | Compositions and methods for improving persistence of cells for adoptive transfer |
| JP2021506243A (ja) * | 2017-12-13 | 2021-02-22 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞受容体及びβ２ミクログロブリン発現を排除するように遺伝子改変された不死化ＣＡＲ−Ｔ細胞 |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| US11227325B1 (en) | 2017-12-18 | 2022-01-18 | Wells Fargo Bank, N.A. | Event-based automatic transaction system |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| WO2019154313A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| WO2019161271A1 (en) * | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| CA3091136A1 (en) * | 2018-02-16 | 2019-08-22 | Kyoto University | Method for producing low-antigenic cell |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| US20210015869A1 (en) | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| RU2020135968A (ru) | 2018-04-05 | 2022-05-06 | Джуно Терапьютикс, Инк. | T-клеточные рецепторы и модифицированные клетки, экспрессирующие |
| IL277883B2 (en) | 2018-04-12 | 2023-12-01 | Prec Biosciences Inc | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| US20190247437A1 (en) * | 2018-04-19 | 2019-08-15 | APDN (B.V.I.), Inc. | Engineered lymphocyte compositions, methods and systems |
| US12054529B2 (en) | 2018-04-20 | 2024-08-06 | Medizinische Hochschule Hannover | Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN112752767A (zh) * | 2018-04-27 | 2021-05-04 | 克里斯珀医疗股份公司 | 细胞毒性t细胞耗竭的方法和组合物 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| JP2022511345A (ja) * | 2018-09-21 | 2022-01-31 | カファ セラピューティクス リミテッド | ＣＲＩＳＰＲ／Ｃａｓシステムに基づいた細胞の遺伝子編集の方法 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| JP7553440B2 (ja) * | 2018-11-07 | 2024-09-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 抗ｃｄ３３免疫細胞癌療法 |
| CN113015750A (zh) * | 2018-11-07 | 2021-06-22 | 克里斯珀医疗股份公司 | 抗liv1免疫细胞癌症疗法 |
| CN111349606A (zh) * | 2018-12-20 | 2020-06-30 | 上海恒润达生生物科技有限公司 | P60抑制剂与cart细胞联合应用 |
| CN113544273A (zh) * | 2019-01-07 | 2021-10-22 | 加利福尼亚大学董事会 | 合成的分子反馈回路及其使用方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN109706121A (zh) * | 2019-01-25 | 2019-05-03 | 苏州茂行生物科技有限公司 | 一种基于碱基编辑的通用型car-t细胞及其制备方法和应用 |
| WO2020168122A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) * | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| GB2601617B (en) | 2019-03-19 | 2024-02-21 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| KR20240122580A (ko) | 2019-04-03 | 2024-08-12 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN111826352A (zh) * | 2019-04-22 | 2020-10-27 | 苏州方德门达新药开发有限公司 | 通用型car-t细胞、其制备及应用 |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| US20220233593A1 (en) * | 2019-06-04 | 2022-07-28 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| TW202115245A (zh) * | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
| WO2020259707A1 (zh) * | 2019-06-28 | 2020-12-30 | 科济生物医药（上海）有限公司 | 抗移植反应的细胞和方法 |
| CN114729028B (zh) * | 2019-08-29 | 2025-05-23 | 克莱格医学有限公司 | 抗移植反应的细胞和方法 |
| KR20220052370A (ko) * | 2019-09-05 | 2022-04-27 | 크리스퍼 테라퓨틱스 아게 | 보편적 공여자 세포 |
| US11116798B2 (en) * | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4048295A1 (en) | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN120485123A (zh) * | 2019-11-05 | 2025-08-15 | 隆萨沃克斯维尔股份有限公司 | 同种异体t细胞和其产生方法 |
| AR120538A1 (es) * | 2019-11-25 | 2022-02-23 | Univ Kyoto | Banco de células maestras de células t |
| WO2021130250A1 (en) | 2019-12-23 | 2021-07-01 | Cellectis | New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| CN115335508A (zh) * | 2020-01-23 | 2022-11-11 | 康干细胞生物科技有限公司 | 成品干细胞及免疫细胞、包含其的药物组合物 |
| WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
| JP2023522985A (ja) * | 2020-04-23 | 2023-06-01 | エーゼットセラピーズ， インコーポレイテッド | Ｈｌａクラスｉ ｍｈｃの細胞切除 |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| KR20230024984A (ko) | 2020-06-12 | 2023-02-21 | 엔카르타, 인크. | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| EP4176261A1 (en) | 2020-07-03 | 2023-05-10 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
| WO2022007784A1 (en) * | 2020-07-06 | 2022-01-13 | Nanjing Legend Biotech Co., Ltd. | Methods of reducing graft rejection of allogeneic cell therapy |
| KR20220005208A (ko) * | 2020-07-06 | 2022-01-13 | 주식회사 지씨셀 | 면역원성이 감소된 신규한 이식용 세포 |
| US20230248825A1 (en) | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| MX2023001244A (es) | 2020-07-31 | 2023-05-16 | Cellectis Sa | Celulas t que expresan dos car. |
| IL300629A (en) * | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of EGFR positive cancer |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN114657137A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| WO2022171179A1 (zh) | 2021-02-10 | 2022-08-18 | 苏州克睿基因生物科技有限公司 | 一种扩增增强子及其应用 |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| TW202304480A (zh) | 2021-03-19 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法 |
| CN118019546A (zh) | 2021-03-23 | 2024-05-10 | 艾欧凡斯生物治疗公司 | 肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途 |
| MX2023012760A (es) | 2021-04-30 | 2023-11-13 | Cellectis Sa | Nuevos cars anti-muc1 y celulas inmunitarias editadas geneticamente para inmunoterapia contra el cancer de tumores solidos. |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| CA3218475A1 (en) | 2021-05-21 | 2022-11-24 | Shipra DAS | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| EP4347810A4 (en) * | 2021-05-24 | 2025-06-04 | Sangamo Therapeutics, Inc. | ZINC FINGER NUCLEASES TARGETING CIITA |
| US20240365776A1 (en) | 2021-07-22 | 2024-11-07 | Iovance Biotherapeutics, Inc | Method for cryopreservation of solid tumor fragments |
| US20240374722A1 (en) * | 2021-08-24 | 2024-11-14 | Cells & Genes Biotech (Shanghai) Co., Ltd | T cell product and use thereof |
| WO2023039041A1 (en) * | 2021-09-10 | 2023-03-16 | Tmunity Therapeutics Inc. | Alternative generation of allogeneic human t cells |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| EP4469579A4 (en) * | 2022-01-25 | 2025-10-29 | Brl Medicine Inc | MODIFIED CELLS AND THEIR USES |
| CA3243419A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES |
| US20250135001A1 (en) * | 2022-02-09 | 2025-05-01 | Carsgen Life Sciences Co., Ltd. | Compositions and methods for cellular immunology |
| CA3246397A1 (en) * | 2022-03-22 | 2023-09-28 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| US20250325585A1 (en) * | 2022-04-15 | 2025-10-23 | The General Hospital Corporation | Compositions and methods for reducing cell therapy immunogenicity |
| CN117004604A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种ciita基因被敲除的工程化免疫细胞及其用途 |
| CA3251533A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST |
| EP4282963A1 (en) | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
| CN114958768B (zh) * | 2022-06-02 | 2023-03-24 | 健颐生物科技发展(山东)有限公司 | Fgf10旁分泌通用型人成纤维细胞制剂的制备方法 |
| US20250281613A1 (en) | 2022-06-30 | 2025-09-11 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
| CN117384852A (zh) * | 2022-07-11 | 2024-01-12 | 士泽生物医药（苏州）有限公司 | 一种表达lgals9的通用型细胞及其制备方法 |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024094775A1 (en) | 2022-11-03 | 2024-05-10 | Cellectis S.A. | Enhancing efficacy and safety of t-cell-mediated immunotherapy |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024121385A1 (en) | 2022-12-09 | 2024-06-13 | Cellectis S.A. | Two-dose regimen in immunotherapy |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| CN119351338A (zh) * | 2023-09-15 | 2025-01-24 | 士泽生物医药（苏州）有限公司 | 一种表达cd300ld的低免疫原性细胞及其制备方法 |
| WO2025235851A1 (en) | 2024-05-10 | 2025-11-13 | Juno Therapeutics, Inc. | Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| CA2113089C (en) * | 1991-07-15 | 2007-11-06 | Peter J. Sims | Universal donor cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
| US20060222633A1 (en) | 2000-05-11 | 2006-10-05 | Yale University | Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| WO2004083379A2 (en) | 2003-03-14 | 2004-09-30 | Walters Richard E | Large volume ex vivo electroporation method |
| US20080260727A1 (en) * | 2004-04-05 | 2008-10-23 | The Regents Of The University Of California | Modulation of Nkg2d |
| EP2325307A1 (en) | 2005-03-15 | 2011-05-25 | Cellectis | I-crel meganuclease variants with modified specificity, method of preparation and uses thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2008102199A1 (en) * | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| FR2931485B1 (fr) | 2008-05-23 | 2011-06-17 | Centre Nat Rech Scient | Vaccin antitumoral comprenant des cellules tumorales modifiees |
| US8945868B2 (en) | 2010-07-21 | 2015-02-03 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a HLA locus |
| EP3320910A1 (en) | 2011-04-05 | 2018-05-16 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| WO2012145384A1 (en) | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| TWI571513B (zh) * | 2011-09-28 | 2017-02-21 | 幹細胞生物科技股份有限公司 | 體幹細胞及其製備方法 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| PT2838548T (pt) * | 2012-04-17 | 2023-10-13 | Univ Washington Through Its Center For Commercialization | Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas |
| EP2855666B1 (en) | 2012-05-25 | 2019-12-04 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US20140230083A1 (en) | 2012-07-24 | 2014-08-14 | Cellectis | Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
| JP2016510594A (ja) | 2013-03-05 | 2016-04-11 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｔリンパ球におけるヘパラナーゼの発現 |
| US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| EP2971288A4 (en) | 2013-03-14 | 2016-12-07 | Elwha Llc | COMPOSITIONS, METHODS AND COMPUTER SYSTEMS FOR THE MANUFACTURE AND ADMINISTRATION OF MODIFIED T CELLS |
| WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| CN115261411A (zh) * | 2013-04-04 | 2022-11-01 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
| WO2015037760A1 (ko) | 2013-09-13 | 2015-03-19 | 볼보 컨스트럭션 이큅먼트 에이비 | 건설기계용 플로트 밸브 |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| EP3268388A1 (en) * | 2015-03-11 | 2018-01-17 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| HK1249351A2 (zh) * | 2015-05-15 | 2018-10-26 | 奥罗皮艇有限公司 | 可折叠船只 |
-
2015
- 2015-03-11 RU RU2016139643A patent/RU2752933C2/ru active
- 2015-03-11 ES ES15709185T patent/ES2782125T3/es active Active
- 2015-03-11 EP EP15709185.1A patent/EP3116902B1/en not_active Revoked
- 2015-03-11 EP EP24153261.3A patent/EP4368705B1/en active Active
- 2015-03-11 JP JP2016556702A patent/JP6681837B2/ja active Active
- 2015-03-11 PT PT157091851T patent/PT3116902T/pt unknown
- 2015-03-11 PL PL19219954.5T patent/PL3693384T3/pl unknown
- 2015-03-11 ES ES19219954T patent/ES2978312T3/es active Active
- 2015-03-11 AU AU2015228844A patent/AU2015228844B2/en active Active
- 2015-03-11 US US15/123,974 patent/US20170016025A1/en not_active Abandoned
- 2015-03-11 CA CA2942113A patent/CA2942113C/en active Active
- 2015-03-11 PL PL15709185T patent/PL3116902T3/pl unknown
- 2015-03-11 BR BR112016019071A patent/BR112016019071A8/pt active Search and Examination
- 2015-03-11 PT PT192199545T patent/PT3693384T/pt unknown
- 2015-03-11 DK DK24153261.3T patent/DK4368705T3/da active
- 2015-03-11 MX MX2016010923A patent/MX373460B/es active IP Right Grant
- 2015-03-11 PL PL24153261.3T patent/PL4368705T3/pl unknown
- 2015-03-11 WO PCT/EP2015/055097 patent/WO2015136001A1/en not_active Ceased
- 2015-03-11 DK DK15709185.1T patent/DK3116902T3/da active
- 2015-03-11 HU HUE15709185A patent/HUE048558T2/hu unknown
- 2015-03-11 DK DK19219954.5T patent/DK3693384T5/da active
- 2015-03-11 ES ES24153261T patent/ES3017080T3/es active Active
- 2015-03-11 KR KR1020167028153A patent/KR102228828B1/ko active Active
- 2015-03-11 HU HUE24153261A patent/HUE070821T2/hu unknown
- 2015-03-11 EP EP19219954.5A patent/EP3693384B1/en active Active
- 2015-03-11 HU HUE19219954A patent/HUE066758T2/hu unknown
- 2015-03-11 CN CN201580012829.6A patent/CN106103475B/zh active Active
- 2015-03-11 PT PT241532613T patent/PT4368705T/pt unknown
-
2016
- 2016-08-02 IL IL247064A patent/IL247064B/en active IP Right Grant
-
2018
- 2018-09-21 US US16/138,908 patent/US11820996B2/en active Active
-
2020
- 2020-03-24 JP JP2020051964A patent/JP7105266B2/ja active Active
-
2023
- 2023-10-04 US US18/480,890 patent/US12252699B2/en active Active
-
2025
- 2025-02-28 US US19/067,358 patent/US20250277231A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508468A5 (cg-RX-API-DMAC7.html) | ||
| RU2016139643A (ru) | Способ создания т-клеток, пригодных для аллогенной трансплантации | |
| CN113993999B (zh) | 包含microRNA适应的shRNA(shRNAmiR)的遗传修饰的免疫细胞 | |
| JP2017506894A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells | |
| JP6608807B2 (ja) | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 | |
| AU2018396083B2 (en) | Method for improving production of CAR T cells | |
| JP7252135B2 (ja) | 遺伝子療法 | |
| Zappasodi et al. | Lymphoma immunotherapy: current status | |
| JP2020518276A (ja) | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 | |
| JP2025131624A (ja) | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ | |
| JP2017506894A (ja) | 制御性ｔ細胞をインサイチューで阻害するための方法 | |
| US20220273720A1 (en) | Lymphodepletion dosing regimens for cellular immunotherapies | |
| EP4284823A1 (en) | Modulation of tgf beta signaling in genetically-modified eukaryotic cells | |
| Nakanishi et al. | Synthetic mRNA for ex vivo therapeutic applications | |
| Hildebrandt et al. | Immunotherapy: opportunities, risks and future perspectives | |
| Roszkowski et al. | Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells | |
| CN106478823B (zh) | Her1靶向性的嵌合抗原受体和nkt细胞及其制法和应用 | |
| AU2024206812A1 (en) | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene | |
| US20230192807A1 (en) | Methods for immunotherapy | |
| JPWO2021034964A5 (cg-RX-API-DMAC7.html) |